NCT04175834View on ClinicalTrials.gov

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

PHASE3CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

May 13, 2022

Study Completion Date

May 13, 2022

Conditions

Multiple SclerosisInfusion Reaction

Interventions

DRUG

cetrizine

prophylaxis

DRUG

diphenhydramine

prophylaxis

Trial Locations (1)

97225

Providence Neurological Specialties West, Portland

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Providence Health & Services

OTHER

NCT04175834 - Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab | Biotech Hunter | Biotech Hunter